TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The CDC’s 2026 Antimicrobial Resistance Threats Report lists 19 pathogens across three threat levels and identifies six more for its watch list. Together, the pathogens are estimated to cause 9.7 million infections and 50,800 deaths annually in the United States; four drug-resistant threats received the agency’s top “urgent” ranking.
The CDC’s 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens posing public health risks and estimates that the listed pathogens collectively cause 9.7 million infections and 50,800 deaths in the United States each year. Four drug-resistant pathogens—including Candida auris and drug-resistant gonorrhea—are classified as “urgent,” the agency’s highest threat level.
The CDC places pathogens in categories ranging from concerning and serious to urgent, and separately identifies six organisms on a watch list of potential threats. The urgent category signals that the agency considers the pathogens to require aggressive action. The report names C. auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae as its four urgent drug-resistant threats.
The report also records changes to the list. Drug-resistant N. meningitidis is classified as a serious threat requiring prompt, sustained action. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria were added to the watch list. Clostridioides difficile moved down from urgent to serious; the CDC attributes the change in part to infection-prevention measures that have reduced cases since 2011.
Several figures in the report describe specific pathogens in 2023, rather than annual totals for every year. Carbapenem-resistant Acinetobacter was associated with an estimated 9,497 U.S. hospitalizations and 817 deaths that year. Carbapenem-resistant Enterobacterales were associated with 14,878 hospitalizations and an estimated 1,252 deaths. The figures and estimates have different scopes from the report’s combined annual totals and should not be treated as directly interchangeable.
How Resistance Affects Patient Care
Antimicrobial resistance can make infections harder to treat when medicines that would normally work no longer do. That matters not only for people who develop an infection: drug-resistant infections can complicate hospital care, particularly for patients already seriously ill or undergoing procedures that carry infection risks.
Wendy Armstrong, president of the Infectious Diseases Society of America, said in a statement that resistant infections can prolong hospital stays and increase healthcare costs. She also warned that they can make it more difficult for doctors to provide treatments such as chemotherapy, organ transplants and joint replacements safely. Those are her comments on the implications of the report; the CDC’s headline estimates quantify the combined burden of the listed pathogens, not the effect on any individual patient or procedure.
The urgent classifications also focus attention on the limited treatment options for some infections. Drug-resistant gonorrhea, for example, can make treatment more difficult, while carbapenem-resistant bacteria can affect hospitalized and nursing-home patients. The report provides a national overview of threats; it does not mean that every listed infection is equally common or poses the same risk to every person.
Products Worth Considering
Levoit Core 600S-P Smart Air Purifier for Large Rooms up to 2933 ft²
Levoit Vital Pet Pro Smart Air Purifier
Oral-B iO Series 5 Rechargeable Electric Toothbrush with 3 Brush Heads and Travel Case, Black
As an affiliate, we earn on qualifying purchases.
New Additions and Changed Ratings
The report is an updated assessment of antimicrobial resistance threats in the United States. It organizes pathogens by threat level and includes a watch list for organisms the CDC considers potential emerging concerns. The watch-list designation reflects uncertainty about their disease burden and potential to become a broader threat; it is not the same as the urgent classification.
The report’s examples show why the categories matter. CDC data cited in the source report record 4,523 reported U.S. C. auris cases in 2023, compared with 48 in 2016, when the infection was first reported in the United States. The comparison describes reported cases in those two years; it does not by itself establish the reasons for the change. C. auris can cause severe infections, especially among people with serious underlying medical conditions.
For gonorrhea, the source says drug-resistant N. gonorrhoeae caused an estimated 787,000 U.S. infections in 2023. It also reports that 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations. The CDC report’s category changes include both pathogens newly added to its lists and C. difficile’s move from urgent to serious.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Report’s Estimates
The report’s combined estimate of 9.7 million infections and 50,800 deaths annually covers the pathogens included in its assessment. The source material does not specify the exact estimation period or explain how much each pathogen contributes to the combined total, so the figures should not be read as deaths caused solely by the four urgent threats.
The CDC also added organisms to its watch list despite uncertainty about their disease burden. The available material does not provide detailed estimates for those newer entries or say whether they will move into a higher category. It also does not give a timetable for future reassessment. Changes in a category, including C. difficile’s move to serious, should not be interpreted as a claim that the organism poses no threat.
Policy and Surveillance Ahead
Armstrong urged Congress to pass the PASTEUR Act, which would create a federal program to support development of antimicrobial drugs targeting the most threatening pathogens and infections. According to the source report, versions of the bill remain stalled in congressional committees. The source does not identify a scheduled vote or provide a timeline for further action.
For now, the CDC’s updated rankings provide a reference for public health and healthcare planning, while the watch-list additions mark areas where the agency sees potential concern but where disease burden remains uncertain. The next developments to watch are any movement on the legislation and future CDC reporting on pathogen trends, cases and resistance.
Key Questions
What does the CDC estimate these pathogens cause each year?
The CDC estimates the pathogens included in its report collectively cause 9.7 million infections and 50,800 deaths annually in the United States. The source material does not give a precise estimation period or a breakdown of the total by pathogen.
Which pathogens are on the urgent list?
The four drug-resistant pathogens identified as urgent are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The CDC moved Clostridioides difficile from urgent to serious, citing infection-prevention measures that have helped reduce cases since 2011. The change does not mean the infection is no longer a public health concern.
What is the CDC’s watch list?
The watch list identifies organisms the CDC considers potential threats while their disease burden or future significance remains uncertain. New entries cited in the report include drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria.
What is the PASTEUR Act?
According to the source report, the proposed PASTEUR Act would establish a federal program to develop antimicrobial drugs for the most threatening pathogens and infections. Versions of the legislation remain in congressional committees, with no vote date provided in the source material.
Source: medpagetoday.com
